Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

Table 1 Sample characteristics

	CHT + mEHT, n (%)	CHT, n (%)	P value
Median age (range)	64 (38-82)	69 (34-92)	0.013
M	39 (67)	57 (57)	0.204
F	19 (33)	43 (43)
Non-Metastatic	16 (28)	37 (37)	0.223
Metastatic	42 (72)	63 (63)
Site of Metastases
Liver	40 (61)	51 (70)	0.164
Peritoneum	16 (24)	6 (8)
Lymph nodes	9 (14)	6 (8)
Lung	1 (2)	8 (11)
Previous surgery	14 (24)	24 (24)	0.981
Previous RT	1 (2)	12 (12)	0.023
Previous CHT	52 (90)	52 (52)	< 0.001
Number of previous CHT lines
1	31 (60)	25 (48)	0.334
2	10 (19)	18 (35)	0.037
> 3	11 (21)	9 (17)	0.619
Type of CHT
Gemox	28 (54)	12 (23)	0.004
Gemcitabine	12 (23)	7 (13)	0.205
Gemcitabine abraxane	16 (31)	15 (29)	0.830
FOLFIRINOX	0 (0)	5 (10)	0.022
FOLFOX	0 (0)	4 (8)	0.041
Other	2 (4)	9 (17)

Significative values were reported in bold. mEHT: Modulated electro-hyperthermia; CHT: Chemotherapy; RT: Radiotherapy.

Table 2 Tumor response at 3 mo

	CHT + mEHT, n (%)	CHT, n (%)	P value
DCR	53 (95)	40 (58)	< 0.001
PR	29 (52)	13 (14)	< 0.001
SD	24 (43)	27 (28)	0.064
PD	3 (5)	56 (58)	< 0.001

Significative values were reported in bold. mEHT: Modulated electro-hyperthermia; CHT: Chemotherapy; DCR: Disease control rate; PR: Partial response; SD: Stable disease; PD: Progressive disease.